Unknown

Dataset Information

0

The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors.

ABSTRACT: The clinically used antibiotic Furagin and its derivatives possess inhibitory activity on human (h) carbonic anhydrases (CA, EC 4.2.1.1), some of which are highly expressed in various tissues and malignancies (hCA IX/XII). Furagin exhibited good hCA IX and XII inhibition with KIs of 260 and 57 nM, respectively. It does not inhibit off-target CA I and poorly inhibited CA II (KI = 9.6 μM). Some synthesised Furagin derivatives with aminohydantoin moieties as zinc binding group exhibited weak inhibition of CA I/II, and good inhibition of CA IX/XII with KIs ranging from 350 to 7400 and 150 to 5600 nM, respectively. Docking and molecular dynamics simulations suggest that selectivity for the cancer-associated CA IX/XII over CA II is due to strong H-bond interactions in CA IX/XII, involving the tail orientated towards hydrophobic area of the active site. These results suggest a possible drug repurposing of Furagin as anti-cancer agent.

SUBMITTER: Pustenko A 

PROVIDER: S-EPMC7178874 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors.

Pustenko Aleksandrs A   Nocentini Alessio A   Gratteri Paola P   Bonardi Alessandro A   Vozny Igor I   Žalubovskis Raivis R   Supuran Claudiu T CT  

Journal of enzyme inhibition and medicinal chemistry 20201201 1

The clinically used antibiotic Furagin and its derivatives possess inhibitory activity on human (h) carbonic anhydrases (CA, EC 4.2.1.1), some of which are highly expressed in various tissues and malignancies (hCA IX/XII). Furagin exhibited good hCA IX and XII inhibition with <i>K</i><sub>I</sub>s of 260 and 57 nM, respectively. It does not inhibit off-target CA I and poorly inhibited CA II (<i>K</i><sub>I</sub> = 9.6 μM). Some synthesised Furagin derivatives with aminohydantoin moieties as zinc  ...[more]

Similar Datasets

Unknown Discovery of the first-in-class potent and isoform-selective human carbonic anhydrase III inhibitors.
| S-EPMC10128460 | biostudies-literature
Unknown Development of Novel Quinoline-Based Sulfonamides as Selective Cancer-Associated Carbonic Anhydrase Isoform IX Inhibitors.
| S-EPMC8541628 | biostudies-literature
Unknown Design, Synthesis and Biological Assessment of Rhodanine-Linked Benzenesulfonamide Derivatives as Selective and Potent Human Carbonic Anhydrase Inhibitors.
| S-EPMC9697818 | biostudies-literature
Unknown Carbonic Anhydrase Inhibition with Sulfonamides Incorporating Pyrazole- and Pyridazinecarboxamide Moieties Provides Examples of Isoform-Selective Inhibitors.
| S-EPMC8625619 | biostudies-literature
Unknown Predicting Isoform-Selective Carbonic Anhydrase Inhibitors via Machine Learning and Rationalizing Structural Features Important for Selectivity.
| S-EPMC7876851 | biostudies-literature
Unknown Glycomimetic Based Approach toward Selective Carbonic Anhydrase Inhibitors.
| S-EPMC7236246 | biostudies-literature
Unknown Synthetic Approaches to Novel Human Carbonic Anhydrase Isoform Inhibitors Based on Pyrrol-2-one Moiety.
| S-EPMC10895679 | biostudies-literature
Unknown Synthesis and biological evaluation of new 3-substituted coumarin derivatives as selective inhibitors of human carbonic anhydrase IX and XII.
| S-EPMC10013565 | biostudies-literature
Unknown Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors.
| S-EPMC4355338 | biostudies-literature
Unknown Ureidobenzenesulfonamides as Selective Carbonic Anhydrase I, IX, and XII Inhibitors.
| S-EPMC10707797 | biostudies-literature